Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)

NCT05768711 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT05768711
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05768711 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 4, 2023
Completion date
October 31, 2028
Enrollment
44 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia